![Drug resistant E. coli could be rapidly detected using newly developed technique. [NIH]](https://www.genengnews.com/wp-content/uploads/2018/08/24661308922_3eb66388f6_o8020087571-218x150.jpg "Dangerous E. coli Strain Reveals Potential New Drug Target")
Sangamo CEO Sandy Macrae, MBChB, PhD, discusses Sangamo’s manufacturing plans, and approach to therapy development in an exclusive interview with GEN Edge during the J.P. Morgan conference . . .
- Bioprocessing
- Genome Editing
- Gene Therapy
- T Cells
- CAR T-Cells
- Cancer
- GEN Edge
- Cell Therapy
- Blood Disorders
- Kidney Diseases
- Rare and Neglected Diseases
Sangamo CEO Looks Long-Term toward In Vivo Genome Editing, Regulation
Sandy Macrae, MBChB, PhD, Discusses New Manufacturing Facilities, Expanding Pipeline Beyond Gene Therapy into Newer Technologies with GEN Edge
Sangamo CEO Sandy Macrae, MBChB., PhD, lays out his company’s three-prong approach to developing new treatments during his presentation at the recent J.P. Morgan 38th Healthcare Conference [Sangamo Therapeutics via Twitter]
